Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Net Cash Flow (2023 - 2025)

Historic Net Cash Flow for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to -$7.0 million.

  • Mereo BioPharma's Net Cash Flow rose 1360.78% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.5 million, marking a year-over-year decrease of 31250.25%. This contributed to the annual value of $12.6 million for FY2024, which is 19290.03% up from last year.
  • Per Mereo BioPharma's latest filing, its Net Cash Flow stood at -$7.0 million for Q3 2025, which was up 1360.78% from -$7.8 million recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma's Net Cash Flow ranged from a high of $38.9 million in Q2 2024 and a low of -$9.7 million during Q1 2023
  • Its 3-year average for Net Cash Flow is -$2.2 million, with a median of -$7.8 million in 2025.
  • Data for Mereo BioPharma's Net Cash Flow shows a peak YoY increase of 60139.28% (in 2024) and a maximum YoY decrease of 17679.13% (in 2024) over the last 5 years.
  • Quarter analysis of 3 years shows Mereo BioPharma's Net Cash Flow stood at -$6.8 million in 2023, then crashed by 39.34% to -$9.5 million in 2024, then grew by 25.91% to -$7.0 million in 2025.
  • Its Net Cash Flow was -$7.0 million in Q3 2025, compared to -$7.8 million in Q2 2025 and -$8.2 million in Q1 2025.